Skip to content
OpenCapital
Get started

Esperion Therapeutics ESPR Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

Viatris logo
ViatrisVTRS
——
Absci Corporation logo
Absci CorporationABSI
——

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K—
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%—

Returns & leverage

See full
Return on equity-260.8%—
Debt / equity0.8×—
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's share based compensation arrangement by share based payment award options exercisable number?
Esperion Therapeutics (ESPR) reported share based compensation arrangement by share based payment award options exercisable number of $3.78M in Q1 2026.
How has Esperion Therapeutics's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?
Esperion Therapeutics's share based compensation arrangement by share based payment award options exercisable number increased by 34.0% year-over-year, from $2.82M to $3.78M.
What is the long-term trend for Esperion Therapeutics's share based compensation arrangement by share based payment award options exercisable number?
Over 5 years (2020 to 2025), Esperion Therapeutics's share based compensation arrangement by share based payment award options exercisable number has grown at a 0.8% compound annual growth rate (CAGR), from $3.36M to $3.5M.